Epidemiology of echinocandin resistance in Candida

Details

• Alternative Title:
  Curr Fungal Infect Rep
• Personal Author:
  Grossman, Nina T. ; Chiller, Tom M. ; Lockhart, Shawn R.
• Description:
  Echinocandins are the newest antifungal agents approved for use in treating | infections in the US. They act by interfering with 1,3-β-D-glucan synthase and therefore disrupt cell wall production and lead to | cell death. There is no intrinsic resistance to echinocandins among | species, and isolates from historic collections archived before the release of the echinocandins show no resistance. Resistance to the echinocandins remains low among most | species and ranges overall from 0-1%. Among isolates of |, the proportion of resistant isolates is higher and has been reported to be as high as 13.5% in at least one hospital. Antifungal resistance is due to specific amino acid mutations in the Fksp subunit(s) of the 1,3-β-D-glucan synthase protein which are localized to one of two hotspots. These mutations are being recognized in isolates from patients who have failed echinocandin therapy, and often lead to a poor outcome. While the future looks bright for the echinocandins against most | species, | remains a species of concern and resistance rates of | to the echinocandins should be monitored closely.
• Subjects:
  Anidulafungin Antifungal Article Candida Caspofungin Echinocandin Epidemiology Micafungin
• Source:
  Curr Fungal Infect Rep. 8(4):243-248
• Pubmed ID:
  29780439
• Pubmed Central ID:
  PMC5956517
• Document Type:
  Journal Article
• Funding:
  CC999999/Intramural CDC HHSUnited States/
• Volume:
  8
• Issue:
  4
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:d620f20170bad1a791d28e7a42f030ecdd6f36801854dba026392e2d35a9f315
• Download URL:
  https://stacks.cdc.gov/view/cdc/55070/cdc_55070_DS1.pdf
• File Type:
  [PDF - 307.70 KB ]